| Entry |
|
|---|
| Name |
Insulin aspart (USP/INN);
Insulin aspart (genetical recombination) (JP18);
Insulin aspart (genetical recombination) [Insulin aspart biosimilar 1] (JAN);
Insulin X 14;
NovoRapid (TN);
Novolog (TN) |
|---|
| Product |
.INSULIN ASPART PROTAMINE AND INSULIN ASPART (A-S Medication Solutions), NOVOLOG MIX 70/30 (A-S Medication Solutions), INSULIN ASPART (A-S Medication Solutions), INSULIN ASPART (A-S Medication Solutions), NOVOLOG MIX 70/30 (A-S Medication Solutions), NOVOLOG (A-S Medication Solutions), NOVOLOG MIX 70/30 (A-S Medication Solutions), NOVOLOG MIX 70/30 (Novo Nordisk), INSULIN ASPART (Novo Nordisk Pharma), INSULIN ASPART PROTAMINE AND INSULIN ASPART (Novo Nordisk Pharma), INSULIN ASPART PROTAMINE AND INSULIN ASPART (REMEDYREPACK), NOVOLOG MIX 70/30 (REMEDYREPACK), INSULIN ASPART (REMEDYREPACK), NOVOLOG (REMEDYREPACK), FIASP (Novo Nordisk), WATER INJECTION (Novo Nordisk) |
|---|
| Formula |
C256H381N65O79S6
|
|---|
| Exact mass |
5821.6118
|
|---|
| Mol weight |
5825.5424
|
|---|
| Sequence |
(A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Asn
(B chain) Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Asp Lys Thr
(Disulfide bridge: A6-A11, A7-B7, A20-B19) |
|---|
| Type |
Peptide |
|---|
| Class |
Antidiabetic agent
DG01636 Insulin and analog
DG01796 Insulin analog, fast-acting
Metabolizing enzyme inducer
DG01637 CYP1A2 inducer
|
|---|
| Remark |
| Therapeutic category: | 2492 |
| Product (mixture): | D10570<JP> |
|
|---|
| Efficacy |
Antidiabetic, Insulin receptor agonist |
|---|
| Disease |
|
|---|
| Comment |
insulin analog
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
CYP induction: CYP1A2 [HSA: 1544]
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10A INSULINS AND ANALOGUES
A10AB Insulins and analogues for injection, fast-acting
A10AB05 Insulin aspart
D04475 Insulin aspart (USP/INN) <JP/US>
A10AD Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
A10AD05 Insulin aspart
D04475 Insulin aspart (USP/INN) <JP/US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
Insulins
Insulin, Rapid-acting
Insulin Aspart
D04475 Insulin aspart (USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
24 Hormones
249 Miscellaneous
2492 Pancreatic hormones
D04475 Insulin aspart (USP/INN); Insulin aspart (genetical recombination) (JP18); Insulin aspart (genetical recombination) [Insulin aspart biosimilar 1] (JAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
INSR family
INSR (CD220)
D04475 Insulin aspart (USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D04475 Insulin aspart (genetical recombination)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D04475
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D04475
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D04475
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D04475
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D04475
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
